The Zhitong Finance App learned that on May 14, according to the CDE official website, Cinda Biotech (01801) IBI3003 Domestic Report Clinical Report (acceptance number: CXSL2400313). IBI3003 is a tri-specific antibody targeting GPRC5D/BCMA/CD3. A phase I/II clinical trial was registered on the ClinicalTrials.gov platform last year. The target enrollment of 116 patients with recurrent or refractory multiple myeloma (registration number: NCT06083207) was completed in February of this year.

According to the 2023 financial report, Cinda will conduct early clinical exploration of 10+ ADCs, dual antibodies, and multiple antibodies from 2024 to early 2025, including IBI3003. Furthermore, in the ADC field, it involves a variety of dual-antibody ADCs, IBI3001, a new EGFR/B7H3ADC drug, and IBI133, a new HER3 ADC drug. The latter has now initiated phase I/II clinical trials.